NanoViricides is expected to report a consensus EPS of -$0.11 on zero revenue for the quarter ending June 30, 2026, with the current $1.30 stock price trading at a deep discount to the $6.00 average analyst target. Investors are primarily watching for clinical updates regarding the Phase II trial of NV-387, a broad-spectrum oral gummy antiviral recently initiated for Mpox and Ebola.
Management's latest filings disclosed a 'going concern' warning, as cash reserves of approximately $2.8 million appear insufficient to cover the company's annual operating burn of $7.7 million. This reporting event will be critical for gauging the success of recent capital-raising efforts and the timeline for clinical data that could serve as a major valuation catalyst.